The following examples illustrate the oral compositions and methods of the present invention, and the benefits achieved by the utilization of such compositions and methods. These examples are illustrative of the invention herein and are not to be construed as limiting thereof.
EXAMPLE 1
Selection of Suitable Sources of F.sup.- Fluoride Ions
The percent dissociation of fluoride compounds into free F.sup.- fluoride ions after 10 minutes in aqueous solution is measured as follows. Fluoride measurements are made with an Orion fluoride selective electrode (Orion Catalog No. 940900, "Fluoride Solid-State, epoxy body electrode, U.S. standard connector", Orion Catalog 1986) using an Orion reference electrode (Orion Catalog No. 900100, "Epoxy body, Ag/AgCI internal", Orion Catalog 1986) and an Orion model 601A digital ionalyzer in the millivolt mode. Sample solutions are made at the time of measurement by adding the appropriate amount of water (approximately 20.degree. C.) to the sample powder mix. Fluoride levels are measured within a minute of reconstitution (as soon as the powder appears to be in solution) and at various intervals up to ten minutes after reconstitution. The fluoride electrode response is compared to the appropriate electrode standard curve (which is prepared using a standardized fluoride solution such as the 100 ppm F.sup.- Fluoride Activity standard, Orion Catalog No. 940907, Orion Catalog 1986) to determine free fluoride levels.
Various fluoride-containing compounds and their percent dissociation in water after 10 minutes are listed in Table 1. As Table 1 illustrates, sodium fluoride, stannous fluoride and strontium fluoride are all essentially 100% dissociated after 10 minutes in water; thus these compounds are suitable sources of F.sup.- fluoride ions. By comparison, sodium monofluorophosphate and sodium fluorosilicate are essentially 0% dissociated after 10 minutes in water, and are not suitable sources of F.sup.- fluoride ions in the context of the present invention.
EXAMPLE 2
Mouthrinse Compositions
Mouthrinse concentrate compositions (in solid form) of the present invention comprise the following components:
Mouthrinse compositions of the present invention are prepared by dissolving either concentrate composition A or B in 15 ml of water. Dissolution time is about one minute. The resulting mouthrinse solution contains 1% and 2%, respectively, of magnesium monoperphthalate (87% active). The A.O. concentration of these solutions is approximately 0.065 w/v and 0.13 w/v, respectively.
Rinsing for 30 seconds twice a day for 3 months with the aqueous mouthrinse obtained from composition A or B results in antigingivitis benefit and reduction in the number of pathogenic bacteria in dental plaque, without any accompanying dental stain.
Mouthrinse concentrate compositions and aqueous solutions of the present invention are similarly prepared and used by employing 1,12-dodecanedioic diperoxy acid (without or, preferably, with borate buffer components) instead of the magnesium monoperphthalate of the hereinbefore A and B concentrates. For example, aqueous mouthrinses containing 1,12-dodecanedioic diperoxy acid ("DPDA") have the following components:
Composition C is prepared as follows: Add 1.0 g of 100% ethanol to a container along with 43.75 mg of a DPDA/boric acid mixture (a hydrate which contains approximately 20% water), and then vortex rapidly for 10 seconds. To this mixture add 14.0 g of a solution containing 9% ethanol, 0.73% sodium borate, 1.3% 1N HCl, 0.11% sodium saccharin, 0.037% sodium fluoride, and 89% water (pH of solution approximately 8.5). Vortex the resulting mixture for another 10 seconds. As prepared, Composition C has an A.O. concentration of approximately 120 ppm. Composition D is similarly prepared using the above procedure but using 87.5 mg of DPDA/boric acid and 0.074% sodium fluoride. As prepared, Composition D has an A.O. concentration of approximately 240 ppm.
Mouthrinse concentrate compositions and aqueous solutions of the present invention are similarly prepared and used by substituting in place of sodium fluoride the compounds stannous fluoride or strontium fluoride as the source of F.sup.- fluoride ions.
EXAMPLE 3
Several toothpaste or gel formulations according to the present invention are prepared using procedures taught in U.S. Pat. No. 3,988,433, issued Oct. 26, 1976 to Benedict. Compositions of such formulations are set forth as follows:
Brushing once a day for 30 seconds with 1 ml (approximately 1 gram) of any of the above described toothpastes or gels promotes continued gingival health in persons with healthy gingival tissue by significantly reducing the number of pathogenic bacteria in dental plaque. The compositions are also effective for treating gingivitis. These benefits are obtained without any accompanying dental stain.
EXAMPLE 4
Rat stain and plaque studies are used to evaluate the staining potential and antiplaque efficacy of various formulations. Royalhart Wistar albino rats (Royalhart Laboratory Animals, Inc.; New Hampton, N.Y.) are stratified into groups of 20 animals each (balancing for litter, weight and sex). The test formulations are provided as solutions and are applied topically. Using a micropipetter, 0.25 ml of solution is directed onto the molar teeth of one side of the animal's mouth and another 0.25 ml is applied to the other side of the mouth. Treatments are administered twice daily, five days per week, for a period of three weeks. The first treatment each day is begun at the same time every day, and the second treatment is begun no earlier than six hours after the first treatment.
(a) Molar plaque evaluation:
Two weeks after the treatment phase of the study is initiated, in situ molar plaque is evaluated. This method involves the disclosing (using basic fuschin) of the molar plaque and then estimating the percent coverage of plaque on the mesial surface of the first maxillary molars. This is evaluated by the following scoring system (score and % coverage, respectively):1=.ltoreq.10%; 2=.ltoreq.20%; 3=.ltoreq.30%, 4=.ltoreq.40%; 5=.ltoreq.50%; 6=.ltoreq.60%; 7=.ltoreq.70%; 8=.ltoreq.80%; 9=.ltoreq.90%; and 10=.ltoreq.100%. The score given to each animal is the sum of the two scores obtained from the first maxillary molars. Standard analysis of variance for treatments are ranked by Newman-Keul's method.
(b) Stain assessments:
At the end of the study the animals are sacrificed and the jaws are cleaned free of tissue by autoclaving for 25 minutes. The cleaned jaws are then air dried for 2 days, after which time the jaws are evaluated for stain. Since the greatest amount of stain accumulates on the mesial surface of the first maxillary molar, an accurate evaluation of stain formation can be determined by scoring only this surface. The percent coverage with stained material of the first surface (mesial) of the first maxillary molar is recorded for both maxillae. The average score per rat is the score used for tabulation and analysis. An intensity factor is assigned to each percent coverage score obtained based on a subjective evaluation of thickness and color intensity; i.e., low=1; moderate=2; and heavy=3. An average intensity score is then determined for each group and is used for tabulation and analysis. Standard analysis of variance with treatments are ranked by Wilcoxon's method.
(c) Evaluation
The following formulations are evaluated in one study ("Study #1") versus a deionized water control:
(1) 0.5% magnesium monoperphthalate in carbonate/citrate buffer;
(2) 0.5% magnesium monoperphthalate+500 ppm NaF in carbonate/citrate buffer;
(3) 0.5% magnesium monoperphthalate+500 ppm sodium monofluorophosphate in carbonate/citrate buffer; and
(4) 0.1% chlorhexidine digluconate (hereinafter "chlorhexidine").
Test results from Study #1 for stain and molar plaque for these formuations are provided in Table 2. Of these formulations, only the magnesium monoperphthalate/NaF formulation is not significantly different from the control with regard to stain. Furthermore, all the formulations significantly reduce plaque relative to the control. Thus, it can be concluded that the stain benefit for the magnesium monoperphthalate/NaF formulation is achieved while providing anti-plaque efficacy.
Finally, the following formulations are evaluated in another study ("Study #2") versus a deionized water control:
(1) 0.5% magnesium monoperphthalate in carbonate/citrate buffer;
(2) 0.5% magnesium monoperphthalate+500 ppm NaF in carbonate/citrate buffer;
(3) 0.12% chlorhexidine; and
(4) 500 ppm NaF followed within 10 min. by 0.12% chlorhexidine.
Test results from Study #2 for stain and molar plaque for these formulations are provided in Table 3. These results are consistent with the results of Study #1. In addition, the chlorhexidine and chlorhexidine/NaF formulations produce essentially the same stain, with the chlorhexidine/NaF formulation being directionally more staining.